AlzeCure Pharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	32.97	50.34	31.5	29.1	25.58	41.74
Cash & Short-Term Investments	32.97	50.34	31.5	29.1	25.58	41.74
Cash Growth	58.35%	59.81%	8.24%	13.77%	-38.73%	-62.88%
Accounts Receivable	-	0	0.04	0	-	-
Other Receivables	2.55	3.34	1.77	1.47	1.38	1.54
Total Trade Receivables	2.55	3.34	1.8	1.47	1.38	1.54
Other Current Assets	1.49	1.28	0.61	1.04	43.01	0.92
Total Current Assets	37.01	54.96	33.9	31.61	27.51	44.2
Net Property, Plant & Equipment	3.78	4.06	5.33	0.38	0.85	1.42
Other Intangible Assets	0.02	0.02	0.02	0.02	0.02	0.02
Other Long-Term Assets	-	-	-	-	0.01	0.01
Total Assets	40.81	59.04	39.25	32	70.84	45.65
Accounts Payable	6.54	4.16	2.69	2.69	4.85	5.97
Accrued Expenses	10.33	6.67	5.25	4.95	5.18	6.38
Other Current Liabilities	10.42	12.74	1.61	0.59	0.33	0.32
Total Current Liabilities	27.29	23.56	9.55	8.23	10.35	12.67
Long-Term Leases	2.29	2.56	3.64	-	-	-
Total Long-Term Liabilities	2.29	2.56	3.64	-	-	-
Total Liabilities	29.58	26.12	13.18	8.23	10.35	12.67
Common Stock	2.87	2.87	2.21	1.55	1.55	0.94
Additional Paid-in Capital	453.27	453.27	399.43	362.44	361.98	278.84
Retained Earnings	-444.92	-423.22	-375.57	-340.22	-303.05	-246.81
Shareholders' Equity	11.23	32.92	26.07	23.77	60.48	32.97
Total Liabilities & Equity	40.81	59.04	39.25	32	70.84	45.65
Total Debt	2.29	2.56	3.64	0	0	0
Net Cash (Debt)	30.68	47.78	27.86	29.1	25.58	41.74
Net Cash Growth	-35.79%	71.47%	-4.25%	13.77%	-38.73%	-62.88%
Net Cash Per Share	0.29	0.47	0.36	0.47	0.53	1.09
Book Value	11.23	32.92	26.07	23.77	60.48	32.97
Book Value Per Share	0.10	0.33	0.34	0.38	1.26	0.86
Tangible Book Value	11.21	32.9	26.05	23.76	60.47	32.96
Tangible Book Value Per Share	0.10	0.33	0.34	0.38	1.26	0.86